EPIRUS Biopharma (EPRS) Misses Q3 EPS by 8c; Updates on BOW015 as RA Treatment
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/1/2026
Go back to EPIRUS Biopharma (EPRS) Misses Q3 EPS by 8c; Updates on BOW015 as RA Treatment
November 16, 2015 6:05 AM EST
Readiness for on-time initiation of pivotal global registration study with completion of manufacturing process lockBOW015 remains on track for 2017 global filingBOW015 targets large market opportunity based on $8.8 billion global sales of Remicade®i
BOSTON, Nov. 16, 2015 (GLOBE NEWSWIRE) -- Â EPIRUS Biopharmaceuticals, Inc. (Nasdaq: EPRS), a biopharmaceutical company focused on the global... More
November 16, 2015 6:00 AM EST
BOSTON, Nov. 16, 2015 (GLOBE NEWSWIRE) -- EPIRUS Biopharmaceuticals, Inc. (Nasdaq: EPRS), a biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal antibodies (mAbs), today reported financial results for the third quarter of 2015, and provided a business update.
This is an exciting time for EPIRUS as we bring monoclonal antibody biosimilars to patients worldwide and execute our global strategy of building a robust... More
